Publication:
Halting Disability Progression in Multiple Sclerosis with Immunomodulatory Injectable Treatments: Is It Achievable?

Simple item page
dc.contributor.authorFragoso, Y. D.
dc.contributor.authorSpelman, T.
dc.contributor.authorDuquette, P.
dc.contributor.authorGirard, M.
dc.contributor.authorTrojano, M.
dc.contributor.authorIzquierdo, G.
dc.contributor.authorButzkueven, H.
dc.contributor.authorIDOreja-Guevara, Celia/0000-0002-9221-5716
dc.contributor.authorIDLugaresi, Alessandra/0000-0003-2902-5589
dc.date.accessioned2020-06-21T13:18:04Z
dc.date.available2020-06-21T13:18:04Z
dc.date.issued2017
dc.departmentOMÜen_US
dc.department-temp[Fragoso, Y. D.] Univ Metropolitana Santos, Neurol, Santos, Brazil -- [Spelman, T.] Royal Melbourne Hosp, Dept Med, Melbourne, Vic, Australia -- [Spelman, T.] Royal Melbourne Hosp, Melbourne Brain Ctr, Melbourne, Vic, Australia -- [Duquette, P. -- Girard, M.] CHUM Hop Notre Dame, Quebec City, PQ, Canada -- [Trojano, M.] Univ Bari, Bari, Italy -- [Izquierdo, G.] Hosp Univ Virgen Macarena, Seville, Spainen_US
dc.description7th Joint European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS)-Americas-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ACTRIMS) -- OCT 25-28, 2017 -- Paris, FRANCEen_US
dc.description.abstract…en_US
dc.description.sponsorshipEuropean Comm Treatment & Res Multiple Sclerosis, Americas Comm Treatment & Res Multiple Sclerosisen_US
dc.description.sponsorshipBiogen IdecBiogen; NovartisNovartis; MerckSeronoMerck SeronoMerck & Company; GenzymeGenzyme Corporationen_US
dc.description.sponsorshipYara Dadalti Fragoso, Tim Spelman, Pierre Duquette, Marc Girard, Maria Trojano, Guillermo Izquierdo, Pierre Grammond, Alessandra Lugaresi, Vincent Van Pesch, Francois Grand'Maison, Celia Oreja-Guevara, Gerardo Iuliano, Roberto Bergamaschi, Maria Edite Rio, Ricardo Fernandez Bolanos, Murat Terzi, and Helmut Butzkueven, have no particular conflicts of interest to declare for this abstract. The work was carried out on behalf of MSBase study group, which receives unconditional grants from pharmaceutical industries (Biogen Idec, Novartis, MerckSerono, Genzyme) to support the existence of the database.en_US
dc.identifier.endpage855en_US
dc.identifier.issn1352-4585
dc.identifier.issn1477-0970
dc.identifier.startpage854en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12712/12191
dc.identifier.volume23en_US
dc.identifier.wosWOS:000413730205114
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.journalMultiple Sclerosis Journalen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleHalting Disability Progression in Multiple Sclerosis with Immunomodulatory Injectable Treatments: Is It Achievable?en_US
dc.typeConference Objecten_US
dspace.entity.typePublication

Files

Collections

WoS İndeksli Yayınlar Koleksiyonu